NYU Langone Health

45 marketed · 8 in Phase 3

Quick facts

Founded1841

Marketed products

Phase 3 pipeline

Phase 2 pipeline

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about NYU Langone Health

What are NYU Langone Health's marketed drugs?

Top marketed products include ACB, Acthar high dose (80 U), Acthar low dose (40 U), Adderall ® Immediate Release, Adderall XR ®, Ankle OnQ.

What is NYU Langone Health's pipeline?

NYU Langone Health has 8 drugs in Phase 3, 22 in Phase 2, 9 in Phase 1. Late-stage candidates include Albuterol-sulphate, AT-001, Botulinum Toxin commonly known as BOTOX®, Continuous ketamine infusion.

When was NYU Langone Health founded?

NYU Langone Health was founded in 1841.

Related